Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Poteligeo. Always confirm against the full prescribing information.
100 interactions
Articaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Articaine.
Level 1 evidence
Benzocaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Benzocaine.
Level 1 evidence
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Benzyl alcohol.
Level 1 evidence
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Bupivacaine.
Level 1 evidence
Butamben
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Butamben.
Level 1 evidence
Capsaicin
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Capsaicin.
Level 1 evidence
Chloroprocaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Chloroprocaine.
Level 1 evidence
Cinchocaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Cinchocaine.
Level 1 evidence
Cocaine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Cocaine.
Level 1 evidence
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mogamulizumab.
Level 2 evidence
Diphenhydramine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Diphenhydramine.
Level 1 evidence
Dyclonine
The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Dyclonine.
Poteligeo (Mogamulizumab-Kpkc) has 188 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Poteligeo (Mogamulizumab-Kpkc) has 0 major, 27 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Poteligeo. Always confirm against the full prescribing information.